Weight loss is a real finding, with a setting
In STEP 1, adults without diabetes who had obesity, or overweight with a weight-related condition, lost an average of 14.9% of their starting weight on the semaglutide injection studied. The placebo group lost 2.4%. Both groups had lifestyle support, and the comparison ran for 68 weeks. That's the study behind the familiar weight-loss figure.
This is evidence about the manufactured injection in that trial, not proof of the same outcome from a compounded preparation. It's a meaningful difference. It's also a group average, so it can't tell you how much weight you would lose or how you would feel along the way. I want both thoughts in view.
Stomach trouble deserves more than a footnote
Nausea, vomiting, diarrhea and constipation are common in the Wegovy (semaglutide) label. In a combined look at weight-management trials, digestive problems were usually mild to moderate and temporary. They often appeared while the study treatment was being increased.
“Usually” leaves room for a harder experience. The label also describes severe digestive problems and kidney injury linked to fluid loss. Symptoms don't become trivial because a paper puts them in the common column.
Some warnings need your history
The Wegovy prescribing information includes warnings about pancreatitis, inflammation of the pancreas, and gallbladder disease. It also says Wegovy is not recommended for severe gastroparesis, a condition in which the stomach empties very slowly.
The boxed warning, the prominent warning at the top of the label, concerns thyroid C-cell tumors seen in rodents. Whether semaglutide causes the same tumors in humans is still unknown. That is a reason to read the warning carefully, without turning an animal finding into a claim about human cancer.
The label rules out use with a personal or family history of medullary thyroid carcinoma, a particular thyroid cancer, or MEN 2, an inherited condition affecting hormone-producing glands. It also rules out a previous serious allergy to semaglutide or another product ingredient. A provider needs that history; an online checklist can't clear anyone for treatment.
And what happens later?
A STEP 1 follow-up analysed 327 participants from the original trial. In its semaglutide group, average regain was about two-thirds of the earlier weight loss during the year after treatment and the trial's lifestyle support stopped.
That describes a group average in this smaller follow-up, not what happened to every participant. The follow-up study makes the longer view worth discussing. It doesn't decide how long any one person needs treatment.
Questions about follow-up, side effects and a possible change of plan belong beside the hoped-for benefit. The appointment FAQ offers somewhere to start.